Filtros de búsqueda

Lista de obras de Hartmut Goldschmidt

(18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate

artículo científico publicado en 2015

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy

artículo científico publicado en 2014

A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study

artículo científico publicado en 2009

A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis.

artículo científico publicado en 2016

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

artículo científico publicado en 2010

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

artículo científico publicado en 2019

A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma

artículo científico publicado en 2015

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis

scientific article published on 01 September 2018

A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments

artículo científico publicado en 2008

A reference data model of a metadata registry preserving semantics and representations of data elements

artículo científico publicado en 2014

A systematic classification of death causes in multiple myeloma.

artículo científico publicado en 2018

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

artículo científico publicado en 2006

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.

artículo científico publicado en 2017

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

artículo científico publicado en 2019

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

scientific article published on 08 December 2011

Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation.

artículo científico publicado en 2005

An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when

scholarly article by Jo Caers et al published 31 August 2018 in Haematologica

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

artículo científico publicado en 2008

Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response

artículo científico publicado en 2017

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

artículo científico publicado en 2016

Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity

artículo científico publicado en 2014

Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities

artículo científico publicado en 2015

Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial

artículo científico publicado en 2014

Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology

artículo científico publicado en 2016

Association of antigen-specific T-cell responses with antigen expression and immunoparalysis in multiple myeloma.

artículo científico publicado en 2015

Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study

article

Atypical manifestations of multiple myeloma: radiological appearance

artículo científico publicado en 2006

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

artículo científico publicado en 2019

Autologous Bone Marrow Transplantation in Adult Patients with Acute Lymphoblastic Leukemia ⬇️

artículo científico publicado el 1 de enero de 2003

Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia

artículo científico publicado en 2006

Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.

artículo científico publicado en 2013

Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects

artículo científico publicado en 2020

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.

artículo científico publicado en 2013

BCMA-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives

artículo científico publicado en 2020

Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma

artículo científico publicado en 2016

Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma - subgroup analysis of the prospective GMMG MM5 trial

artículo científico publicado en 2017

Bone involvement in patients with systemic AL amyloidosis mimics lytic myeloma bone disease

scientific article published on 01 June 2008

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

artículo científico publicado en 2013

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

artículo científico publicado en 2005

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

artículo científico publicado en 2018

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

artículo científico publicado en 2020

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials

artículo científico publicado en 2013

Bortezomib-induced peripheral neuropathy: A genome-wide association study on multiple myeloma patients

artículo científico publicado en 2017

CD200 is a new prognostic factor in multiple myeloma

artículo científico publicado en 2006

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma

artículo científico publicado en 2017

Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?

artículo científico publicado en 2020

Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy

artículo científico publicado en 2011

Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis

artículo científico publicado en 2007

Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

article

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

artículo científico publicado en 2015

Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

artículo científico publicado en 2019

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

artículo científico publicado en 2017

Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.

artículo científico publicado en 2018

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

artículo científico publicado en 2017

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups

artículo científico publicado en 2019

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

artículo científico publicado en 2017

Catheter-related infection and thrombosis of the internal jugular vein in hematologic-oncologic patients undergoing chemotherapy: a prospective comparison of silver-coated and uncoated catheters

artículo científico publicado en 2002

Cell-based immunotherapy approaches for multiple myeloma

scientific article published on 06 December 2018

Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma.

artículo científico publicado en 2008

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

scholarly article by Katharina Kriegsmann et al published 29 January 2019 in Blood Cancer Journal

Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma

artículo científico publicado en 2012

Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma

artículo científico publicado en 2016

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

scientific article published on 22 August 2019

Chlorhexidine and silver-sulfadiazine coated central venous catheters in haematological patients--a double-blind, randomised, prospective, controlled trial

artículo científico publicado en 2005

Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone

scientific article published on 04 December 2010

Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.

artículo científico publicado en 2013

Clinical and prognostic role of annexin A2 in multiple myeloma.

artículo científico publicado en 2012

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

artículo científico publicado en 2014

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

artículo científico publicado en 2008

Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma

artículo científico publicado en 2004

Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma

artículo científico publicado en 2010

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation

artículo científico publicado en 2010

Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk

scientific journal article

Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk

scientific journal article

Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma

artículo científico publicado en 2015

Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients

artículo científico publicado en 2017

Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium

artículo científico publicado en 2012

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma

artículo científico publicado en 2015

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

artículo científico publicado en 2011

Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study)

artículo científico publicado en 2019

Current Aspects in Diagnosis and Therapy of Plasma Cell Myeloma

Current multiple myeloma treatment strategies with novel agents: a European perspective

scientific article published on 19 January 2010

Current status and developments in diagnosis and therapy of multiple myeloma

artículo científico publicado en 2009

Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.

artículo científico publicado en 2017

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma

scientific article published on 27 August 2019

Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels

artículo científico publicado en 2018

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance

artículo científico publicado en 2018

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma

artículo científico publicado en 2018

Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma

artículo científico publicado en 2019

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.

artículo científico publicado en 2015

Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion

artículo científico publicado en 2013

DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine

artículo científico publicado en 2013

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

artículo científico publicado en 2018

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic range albuminuria

scientific article published on 27 February 2020

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

artículo científico publicado en 2020

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

artículo científico publicado en 2019

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2016

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

scientific article published on 23 April 2020

Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics

scientific article published on 01 October 2005

Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors

artículo científico publicado en 2012

Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide

artículo científico publicado en 2003

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

scientific article published on 13 February 2020

Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey

artículo científico publicado en 2017

Diagnostic and therapeutic approaches to multiple myeloma patients: 'Real-world' data from representative multicentre treatment surveys in Germany between 2008 and 2011.

artículo científico publicado en 2016

Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology

artículo científico publicado en 2011

Direct evidence for a polygenic etiology in familial multiple myeloma

scientific article published on 07 April 2017

Dissociation of putative graft‐versus‐haematopoiesis and graft‐versus‐myeloma effects in patients with rapidly progressive multiple myeloma* ⬇️

artículo científico publicado el 1 de noviembre de 2003

Do we need cytogenetics in the follow-up of multiple myeloma?

artículo científico publicado en 2019

Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.

artículo científico publicado en 2002

Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.

artículo científico publicado en 2015

Duplication of chromosome arms 9q and 11q: evidence for a novel, 14q32 translocation-independent pathogenetic pathway in multiple myeloma

artículo científico publicado en 2005

Dynamic Contrast-Enhanced Magnetic Resonance Imaging Identifies a Subgroup of Patients with Asymptomatic Monoclonal Plasma Cell Disease and Pathologic Microcirculation

artículo científico publicado en 2009

Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessment of Antiangiogenic Treatment Effects in Multiple Myeloma

artículo científico publicado en 2014

Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers.

artículo científico publicado en 2005

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging of bone marrow in healthy individuals

artículo científico publicado en 2011

Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation

scientific article published on 28 September 2006

Effect of acupuncture compared with placebo-acupuncture at P6 as additional antiemetic prophylaxis in high-dose chemotherapy and autologous peripheral blood stem cell transplantation: a randomized controlled single-blind trial.

artículo científico publicado en 2003

Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone

artículo científico publicado en 2008

Efficacy and outcome of autologous transplantation in rare myelomas.

artículo científico publicado en 2010

Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.

artículo científico publicado en 2017

Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma.

artículo científico publicado en 2015

Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance

artículo científico publicado en 2019

Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction study.

artículo científico publicado en 2018

Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma.

artículo científico publicado en 2004

European perspective on multiple myeloma treatment strategies in 2014

artículo científico publicado en 2014

European perspective on multiple myeloma treatment strategies: update following recent congresses

artículo científico publicado en 2012

Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability

artículo científico publicado en 2008

Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.

artículo científico publicado en 2008

Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells

artículo científico publicado en 2005

Expression of Mucin-1 in multiple myeloma and its precursors: correlation with glycosylation and subcellular localization

artículo científico publicado en 2014

Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells

artículo científico publicado en 2009

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

scientific article published on 09 August 2007

Extramedullary relapse after accidental head injury in a patient with multiple myeloma

scientific article published on 29 June 2014

Familial Cancer: How to Successfully Recruit Families for Germline Mutations Studies? Multiple Myeloma as an Example

artículo científico publicado en 2019

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

article

First-line therapy with Bendamustine/Prednisone/Bortezomib (BPV) - A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients

scientific article published on 10 March 2020

Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis

artículo científico publicado en 2016

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.

artículo científico publicado en 2016

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

artículo científico publicado en 2018

Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient.

artículo científico publicado en 2017

GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo

artículo científico publicado en 2012

Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma

artículo científico publicado en 2008

Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone

article by Tilmann Bochtler et al published 23 January 2014 in Amyloid

Galectin-8 enhances adhesion of multiple myeloma cells to vascular endothelium and is an adverse prognostic factor

artículo científico publicado en 2016

Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells

artículo científico publicado en 2009

Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment.

artículo científico publicado en 2011

Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma

artículo científico publicado en 2009

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

artículo científico publicado en 2010

Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine

artículo científico publicado en 2011

Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma

artículo científico publicado en 2011

Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism

artículo científico publicado en 2017

Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci

artículo científico publicado en 2016

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology ⬇️

scholarly article by Molly Went et al published 21 December 2018 in Blood Cancer Journal

Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients

artículo científico publicado en 2011

Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.

artículo científico publicado en 2011

Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study

article

Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci

artículo científico publicado en 2017

Genome-wide association study identifies multiple susceptibility loci for multiple myeloma ⬇️

artículo científico publicado en 2016

Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma ⬇️

artículo científico publicado en 2016

Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.

artículo científico publicado en 2017

Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma

artículo científico publicado en 2019

Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma

artículo científico publicado en 2019

Genomewide association study on monoclonal gammopathy of unknown significance (MGUS).

artículo científico publicado en 2017

Germline Risk Contribution to Genomic Instability in Multiple Myeloma

Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis

artículo científico publicado en 2015

Going the distance: Are we losing patients along the multiple myeloma treatment pathway?

scientific article published on 29 March 2018

Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays

artículo científico publicado en 2010

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

artículo científico publicado en 2019

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma

artículo científico publicado en 2007

Hepatitis B virus infection is associated with deletion of chromosome 8p in multiple myeloma

artículo científico publicado en 2012

High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.

artículo científico publicado en 2012

High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH

artículo científico publicado en 2005

High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma

scholarly article by Anjan Thakurta et al published 14 March 2019 in Blood

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting.

artículo científico publicado en 2017

High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study

artículo científico publicado en 2004

How to Treat Multiple Myeloma – A Representative Multicentre Treatment Survey ⬇️

artículo científico publicado el 15 de octubre de 2010

Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14).

artículo científico publicado en 2011

IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells

scientific article published on 20 August 2018

IL-6 and MYC collaborate in plasma cell tumor formation in mice

artículo científico publicado en 2009

Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A).

artículo científico publicado en 2006

Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma

scientific article published on 19 March 2008

Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma

artículo científico publicado en 2006

Identification of miRSNPs associated with the risk of multiple myeloma.

artículo científico publicado en 2016

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

scientific article published in Nature Communications

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

scientific article published on 08 June 2018

Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model

scientific article published on 12 March 2020

Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma

artículo científico publicado en 2012

Imaging Features of Multiple Myeloma Extramedullary Lesions in the Liver with 18F-FDG PET/CT, Contrast-Enhanced CT and MRI

artículo científico publicado en 2019

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

artículo científico publicado en 2015

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2018

Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma

artículo científico publicado en 2016

Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis

artículo científico publicado en 2005

Indications for liver transplantation in patients with amyloidosis: a single-center experience with 11 cases.

artículo científico publicado en 2005

Induction of angiogenesis by normal and malignant plasma cells.

artículo científico publicado en 2009

Infiltration patterns in monoclonal plasma cell disorders: correlation of magnetic resonance imaging with matched bone marrow histology

artículo científico publicado en 2014

Inherited genetic susceptibility to monoclonal gammopathy of unknown significance

artículo científico publicado en 2014

Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells

artículo científico publicado en 2013

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma

artículo científico publicado en 2009

Insights on Multiple Myeloma Treatment Strategies

artículo científico publicado en 2018

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

artículo científico publicado en 2016

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

artículo científico publicado en 2016

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

artículo científico publicado en 2020

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

artículo científico publicado en 2014

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

scientific article published on 01 June 2019

Intravoxel incoherent motion imaging for assessment of bone marrow infiltration of monoclonal plasma cell diseases

artículo científico publicado en 2013

Involvement of alpha 1-2-fucosyltransferase I (FUT1) and surface-expressed Lewis(y) (CD174) in first endothelial cell-cell contacts during angiogenesis

artículo científico publicado en 2008

JunB is a key regulator of multiple myeloma bone marrow angiogenesis

artículo científico publicado en 2021

Kinetics of peripheral blood stem cell mobilization following G-CSF-supported chemotherapy

artículo científico publicado en 2003

Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma

artículo científico publicado en 2013

Kyphoplasty in patients with multiple myeloma a retrospective comparative pilot study

artículo científico publicado en 2011

Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma

artículo científico publicado en 2011

Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro

artículo científico publicado en 2016

Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment ⬇️

artículo científico publicado el 21 de septiembre de 2010

Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells

artículo científico publicado en 2017

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

artículo científico publicado en 2021

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.

artículo científico

Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation

artículo científico publicado en 2007

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.

artículo científico publicado en 2017

Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma

artículo científico publicado en 2017

Lumbar Bone Marrow Microcirculation Measurements from Dynamic Contrast-Enhanced Magnetic Resonance Imaging Is a Predictor of Event-Free Survival in Progressive Multiple Myeloma

artículo científico publicado en 2007

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial

scientific article published on 11 March 2020

MYEOV is a prognostic factor in multiple myeloma

artículo científico publicado en 2010

Malignancy in renal transplantation

artículo científico publicado en 2004

Management of high-risk Myeloma: an evidence-based review of treatment strategies

artículo científico publicado en 2016

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

artículo científico publicado en 2010

Meeting report of the 4th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma

artículo científico publicado en 2013

Meeting report of the 5th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma

artículo científico publicado en 2015

Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.

artículo científico publicado en 2017

Meeting report of the third Heidelberg myeloma workshop: current status and developments in diagnosis and therapy of multiple myeloma

scientific article published on 30 September 2011

Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.

artículo científico publicado en 2009

Microarray-based understanding of normal and malignant plasma cells

artículo científico publicado en 2006

Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease

artículo científico publicado en 2020

Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging

article by Tobias Bäuerle et al published August 2009 in Radiology

Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression

artículo científico publicado en 2016

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

scientific article published on 26 March 2011

MyelomA Genetics International Consortium

artículo científico

NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm

scientific article published on 01 April 2010

Navigating the treatment landscape in multiple myeloma: which combinations to use and when?

artículo científico publicado en 2019

No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement ⬇️

artículo científico publicado el 1 de diciembre de 2003

Non-invasive predictors of survival in cardiac amyloidosis

scientific article published on 09 March 2007

Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis

artículo científico publicado en 2017

Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders.

artículo científico publicado en 2018

Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial.

artículo científico publicado en 2004

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

artículo científico publicado en 2018

Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration

artículo científico publicado en 2010

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma

artículo científico publicado en 2018

PET/CT studies of multiple myeloma using 18 F-FDG and 18 F-NaF: comparison of distribution patterns and tracers’ pharmacokinetics

artículo científico publicado en 2014

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

article

Parametric histogram analysis of dynamic contrast-enhanced MRI in multiple myeloma: a technique to evaluate angiogenic response to therapy?

artículo científico publicado en 2012

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma

scholarly article by Imad Maatouk et al published 21 January 2019 in Blood Cancer Journal

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

scientific article published on 18 July 2019

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.

artículo científico publicado en 2016

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

artículo científico publicado en 2012

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

scientific article published on 29 October 2019

Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.

artículo científico publicado en 2017

Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma

artículo científico publicado en 2014

Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.

artículo científico publicado en 2002

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

artículo científico publicado en 2016

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

artículo científico publicado en 2013

Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation

artículo científico publicado en 2009

Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma

artículo científico publicado en 2019

Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma

artículo científico publicado en 2004

Potential therapeutic targets in plasma cell disorders: A flow cytometry study.

artículo científico publicado en 2015

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.

artículo científico publicado en 2014

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System ⬇️

artículo científico publicado en 2015

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

artículo científico publicado en 2018

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells.

artículo científico publicado en 2015

Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma

scientific article published on 22 February 2010

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study

artículo científico publicado en 2016

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma

scientific article published on 27 December 2017

Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study

artículo científico publicado en 2015

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation

artículo científico publicado en 2017

Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load

artículo científico publicado en 2013

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

artículo científico publicado en 2010

Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma

artículo científico publicado en 2013

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma

artículo científico publicado en 2018

Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death.

artículo científico publicado en 2007

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial

scientific article published on 26 June 2019

Psychosocial support in patients with multiple myeloma at time of diagnosis: who wants what?

artículo científico publicado en 2013

Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial

artículo científico publicado en 2019

Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma

artículo científico publicado en 2018

Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma

artículo científico publicado en 2017

Quantitative dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma

artículo científico publicado en 2019

Radiotherapy of solitary plasmacytoma

artículo científico publicado en 2011

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma

artículo científico publicado en 2019

Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis

artículo científico publicado en 2007

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transpla

artículo científico publicado en 2016

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

article

Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study.

artículo científico publicado en 2007

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma

artículo científico publicado en 2006

Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma

artículo científico publicado en 2014

Respiratory muscle weakness and inefficient ventilation in heart failure due to light-chain amyloidosis

Response improvement rather than response status after 1st ASCT is a significant prognostic factor for survival benefit from tandem compared to single ASCT in multiple myeloma patients

artículo científico publicado en 2020

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

artículo científico publicado en 2020

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

artículo científico publicado en 2009

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

artículo científico publicado en 2015

Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length.

artículo científico publicado en 2014

Risk stratification in cardiac amyloidosis: novel approaches

artículo científico publicado en 2005

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

artículo científico publicado en 2017

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement

artículo científico publicado en 2015

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

artículo científico publicado en 2016

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

artículo científico publicado en 2020

Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy

artículo científico publicado en 2019

Search for multiple myeloma risk factors using Mendelian randomization

scientific article published on 01 May 2020

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

artículo científico publicado en 2022

Selective elimination of immunosuppressive T cells in patients with multiple myeloma

artículo científico publicado en 2021

Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease.

artículo científico publicado en 2014

Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial

artículo científico publicado en 2016

Single-cell PCR analysis of the immunoglobulin heavy-chain CDR3 region for the diagnosis of leptomeningeal involvement of B-cell malignancies using standard cerebrospinal fluid cytospins

artículo científico publicado en 2004

Sorafenib in patients with refractory or recurrent multiple myeloma

artículo científico publicado en 2013

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition.

artículo científico publicado en 2016

Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis

artículo científico publicado en 2009

Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems

scientific article published on October 2010

Storage Duration of Autologous Stem Cell Preparations Has No Impact on Hematopoietic Recovery after Transplantation

artículo científico publicado en 2016

Storage, Utilization and Disposal of Hematopoietic Stem Cell Products in Multiple Myeloma Patients

scientific article published on 16 May 2020

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.

artículo científico publicado en 2015

Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation

artículo científico publicado en 2016

T cell-based targeted immunotherapies for patients with multiple myeloma

artículo científico

TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.

artículo científico publicado en 2007

Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up

artículo científico publicado en 2011

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.

artículo científico publicado en 2016

Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation

artículo científico publicado en 2013

Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth

artículo científico publicado en 2007

Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL

artículo científico publicado en 2005

Targeting the BRAF V600E mutation in multiple myeloma

artículo científico publicado en 2013

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

artículo científico publicado en 2008

Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma

artículo científico publicado en 2012

The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells

artículo científico publicado en 2014

The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

artículo científico publicado en 2013

The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics.

artículo científico publicado en 2006

The Incidence of Senile Cataract and Glaucoma is Increased in Patients with Plasma Cell Dyscrasias: Etiologic Implications

artículo científico publicado en 2016

The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison

scientific article published on 05 November 2019

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

artículo científico publicado en 2010

The glycome of normal and malignant plasma cells

artículo científico publicado en 2013

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature

artículo científico publicado en 2005

The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression.

artículo científico publicado en 2018

The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide

artículo científico publicado en 2010

The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.

artículo científico publicado en 2006

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma

scholarly article by Mohamed H S Awwad et al published 2018 in OncoImmunology

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor

artículo científico publicado en 2009

The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.

artículo científico publicado en 2011

Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.

artículo científico publicado en 2017

Therapeutic strategies in multiple myeloma: the future role of bendamustine

artículo científico publicado en 2013

Therapy of relapsed and refractory multiple myeloma

artículo científico publicado en 2011

Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma

artículo científico publicado en 2009

Timing of the high-dose therapy in the area of new drugs.

artículo científico publicado en 2011

Transcriptional regulation of the vascular endothelial glycome by angiogenic and inflammatory signalling

artículo científico publicado en 2010

Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes

scientific article published on 20 August 2019

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens

artículo científico publicado en 2015

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

scientific article published on 21 March 2016

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

artículo científico publicado en 2010

Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis

artículo científico publicado en 2007

Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma

artículo científico publicado en 2011

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement

artículo científico publicado en 2010

Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment

artículo científico

Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6.

artículo científico publicado en 2013

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.

artículo científico publicado en 2018

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma

artículo científico publicado en 2016

Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma

artículo científico publicado en 2003

Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant

artículo científico publicado en 2014

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

artículo científico publicado en 2013

[Immunostimulating drugs and cytokines]

artículo científico publicado en 2011

[Stem cells in hematology and oncology]

artículo científico publicado en 2003

miRNAs in multiple myeloma--a survival relevant complex regulator of gene expression

artículo científico

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda